Literature DB >> 18778570

Is migraine a neuropathic pain syndrome?

David M Biondi1.   

Abstract

The understanding of migraine pathophysiology has evolved from the belief that migraine is a vascular disorder, to evidence that better defines migraine as a neurogenic disorder associated with secondary changes in brain perfusion. There is evidence to suggest that the early phase of migraine pain results from neurogenic inflammation affecting cranial blood vessels and dura. Allodynia, hyperalgesia, and expansion of nociceptive fields occur during most well-established migraine attacks. These clinical features of migraine are evocative of those traditionally associated with neuropathic pain. A hypothesis that defines migraine pain as a unique neuropathic pain disorder can imply the potential for neural plasticity and may provide insight into the mechanisms that underlie the transformation of episodic to chronic forms of migraine. The neuropathic pain model of migraine pathophysiology not only paves the way for mechanism-based treatment strategies that can improve the acute and preventive management of migraine attacks, but also opens the door for the discovery of novel therapeutic targets. It also lends momentum to an understanding of clinically intriguing topics such as opiate-induced hyperalgesia and medication-overuse headache (rebound headache), opioid resistance in the treatment of chronic headache, and disease modification in defending against the potential for migraine transformation.

Entities:  

Mesh:

Year:  2006        PMID: 18778570     DOI: 10.1007/s11916-006-0042-y

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  90 in total

1.  The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat.

Authors:  J D Classey; Y E Knight; P J Goadsby
Journal:  Brain Res       Date:  2001-07-13       Impact factor: 3.252

2.  LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

Authors:  C N Sang; N M Ramadan; R G Wallihan; A S Chappell; F G Freitag; T R Smith; S D Silberstein; K W Johnson; L A Phebus; D Bleakman; P L Ornstein; B Arnold; S J Tepper; F Vandenhende
Journal:  Cephalalgia       Date:  2004-07       Impact factor: 6.292

3.  Increased adverse effects of opiates in migraine patients.

Authors:  A Panconesi; B Anselmi; G Franchi
Journal:  Cephalalgia       Date:  1995-04       Impact factor: 6.292

4.  Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors.

Authors:  S R Lu; J L Fuh; W T Chen; K D Juang; S J Wang
Journal:  Cephalalgia       Date:  2001-12       Impact factor: 6.292

5.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

Review 6.  Neurogenic inflammation and migraine: implications for the therapeutics.

Authors:  Stephen J Peroutka
Journal:  Mol Interv       Date:  2005-10

Review 7.  Neuronal plasticity: increasing the gain in pain.

Authors:  C J Woolf; M W Salter
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

8.  Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study.

Authors:  Stewart J Tepper; Carl G H Dahlöf; Andrew Dowson; Lawrence Newman; Hank Mansbach; Martin Jones; Ba Pham; Chris Webster; Reijo Salonen
Journal:  Headache       Date:  2004-10       Impact factor: 5.887

9.  Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.

Authors:  Per Sjøgren; Torsten Jonsson; Niels-Henrik Jensen; Niels-Erik Drenck; Troels Staehelin Jensen
Journal:  Pain       Date:  1993-10       Impact factor: 6.961

10.  Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE.

Authors:  S D Silberstein; J R Silberstein
Journal:  Headache       Date:  1992-10       Impact factor: 5.887

View more
  15 in total

1.  Genome-wide association study reveals three susceptibility loci for common migraine in the general population.

Authors:  Daniel I Chasman; Markus Schürks; Verneri Anttila; Boukje de Vries; Ulf Schminke; Lenore J Launer; Gisela M Terwindt; Arn M J M van den Maagdenberg; Konstanze Fendrich; Henry Völzke; Florian Ernst; Lyn R Griffiths; Julie E Buring; Mikko Kallela; Tobias Freilinger; Christian Kubisch; Paul M Ridker; Aarno Palotie; Michel D Ferrari; Wolfgang Hoffmann; Robert Y L Zee; Tobias Kurth
Journal:  Nat Genet       Date:  2011-06-12       Impact factor: 38.330

Review 2.  Chronic Daily Headache: Mechanisms and Principles of Management.

Authors:  Amy W Voigt; Harry J Gould
Journal:  Curr Pain Headache Rep       Date:  2016-02

3.  Migraine genetics: current findings and future lines of research.

Authors:  A M Persico; M Verdecchia; V Pinzone; V Guidetti
Journal:  Neurogenetics       Date:  2014-12-14       Impact factor: 2.660

4.  The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission.

Authors:  G A Lambert; J B Davis; J M Appleby; B A Chizh; K L Hoskin; A S Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-19       Impact factor: 3.000

Review 5.  Critical role of nociceptor plasticity in chronic pain.

Authors:  David B Reichling; Jon D Levine
Journal:  Trends Neurosci       Date:  2009-09-24       Impact factor: 13.837

6.  Episodic dural stimulation in awake rats: a model for recurrent headache.

Authors:  Michael L Oshinsky; Sumittra Gomonchareonsiri
Journal:  Headache       Date:  2007 Jul-Aug       Impact factor: 5.887

7.  Genetics of recurrent vertigo and vestibular disorders.

Authors:  Irene Gazquez; Jose A Lopez-Escamez
Journal:  Curr Genomics       Date:  2011-09       Impact factor: 2.236

Review 8.  New directions in migraine.

Authors:  Greg A Weir; M Zameel Cader
Journal:  BMC Med       Date:  2011-10-25       Impact factor: 8.775

Review 9.  Genetics of migraine in the age of genome-wide association studies.

Authors:  Markus Schürks
Journal:  J Headache Pain       Date:  2011-11-11       Impact factor: 7.277

Review 10.  Palmitoylethanolamide: A Natural Compound for Health Management.

Authors:  Paul Clayton; Mariko Hill; Nathasha Bogoda; Silma Subah; Ruchitha Venkatesh
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.